CDKN2A and cancer: One good candidate for the latter is the ncRNA ANRIL, which lies antisense to CDKN2A and traverses a noncoding region centromeric to CDKN2A, a region implicated in a range of complex diseases including cancer, type 2 diabetes, periodontitis, and coronary heart disease [106]–[112].